Other
Other income, net (Note 6)
Regeneron Pharmaceuticals Other income, net (Note 6) increased by 14.3% to $201.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 37.5%, from $322.00M to $201.20M. Over 3 years (FY 2022 to FY 2025), Other income, net (Note 6) shows an upward trend with a 111.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementIncome Statement
SectionOther
CategoryOther
SignalHigher is better
VolatilityVolatile
First reportedQ1 2013
Last reportedQ1 2026Apr 29, 2026
How to read this metric
Positive values indicate non-core gains, while negative values indicate non-core losses or interest burdens.
Detailed definition
This captures income or expenses that are not part of the company's core business operations, such as interest income, f...
Peer comparison
Standard line item found in the non-operating section of the income statement for most corporations.
Metric ID:
other_other_nonoperating_income_expenseHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $420.00M | -$16.40M | -$183.80M | -$133.60M | $301.40M | $195.30M | -$70.70M | $85.30M | $17.60M | $193.00M | -$34.60M | $573.30M | $327.30M | $0.00 | $322.00M | $442.80M | $755.80M | $176.00M | $201.20M |
| QoQ Change | — | -103.9% | <-999% | +27.3% | +325.6% | -35.2% | -136.2% | +220.7% | -79.4% | +996.6% | -117.9% | >999% | -42.9% | -100.0% | — | +37.5% | +70.7% | -76.7% | +14.3% |
| YoY Change | — | — | — | -131.8% | >999% | — | +61.5% | +163.8% | -94.2% | -1.2% | +51.1% | +572.1% | >999% | -100.0% | >999% | -22.8% | +130.9% | — | -37.5% |
Range-$183.80M – $755.80M
CAGR-15.1%
Avg YoY Growth+380.0%
Median YoY Growth+56.3%
Other income, net (Note 6) at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's other income, net (note 6)?
- Regeneron Pharmaceuticals (REGN) reported other income, net (note 6) of $201.20M in Q1 2026.
- How has Regeneron Pharmaceuticals's other income, net (note 6) changed year-over-year?
- Regeneron Pharmaceuticals's other income, net (note 6) decreased by 37.5% year-over-year, from $322.00M to $201.20M.
- What is the long-term trend for Regeneron Pharmaceuticals's other income, net (note 6)?
- Over 3 years (2022 to 2025), Regeneron Pharmaceuticals's other income, net (note 6) has grown at a 111.5% compound annual growth rate (CAGR), from $179.30M to $1.70B.
- What does other income, net (note 6) mean?
- Financial gains or losses that fall outside of the company's primary business activities.